Bill > H3622

This bill amends existing Massachusetts law, specifically Chapter 175H, Section 3, Subsection (b), Paragraph (2), to allow pharmaceutical manufacturing companies to offer discounts, rebates, product vouchers, or other reductions in out-of-pocket expenses, such as co-payments and deductibles, for a prescription drug. This provision applies even if the drug has an "AB rated generic equivalent," which means a generic version of the drug has been deemed therapeutically equivalent by the U.S. Food and Drug Administration (FDA). The key condition is that the consumer must provide written verification from a healthcare practitioner, as defined in Chapter 111N, stating that the consumer would benefit from the specific brand-name drug, but its AB rated generic equivalent would not be effective for their treatment. This aims to provide financial relief for individuals who require a particular brand-name prescription drug for medical reasons, even when a generic alternative exists.